Penumbra, Inc. PEN

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

• Zacks Investment Research 1 oct

  IART vs. PEN: Which Stock Is the Better Value Option?

  In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.

  

• Zacks Investment Research 29 sept

  IART or PEN: Which Is the Better Value Stock Right Now?

  A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.

  

• Zacks Investment Research 16 sept

  Reasons to Retain Penumbra Stock in Your Portfolio for Now

  Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.

  

• GlobeNewswire Inc. 25 ago

  Incuvate Files Patent Infringement Lawsuit Against Penumbra

  Incuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.

  

• GlobeNewswire Inc. 6 jul

  GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT

  GuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusion in the lower extremities to enable earlier diagnosis and intervention.